• Deanna Church Brings Reference Genome Expertise to Personalis

    Bio-IT World | Deanna Church, longtime leader of the NCBI contributions to the Genome Reference Consortium, has joined Stanford-area startup Personalis offering genome interpretation and genetic diagnostics. Bio-IT World spoke with her about her new role using the human reference genome that she has contributed so much to.

    Feb 5, 2014

  • Illumina Speaks About Plans for Clinical Sequencing

    Clinical Informatics News | Illumina will use 2014 to continue development of new diagnostic applications for the MiSeqDx, including in the oncology space, and to submit the HiSeq 2500 for FDA approval.

    Feb 4, 2014

  • Thermo Fisher Closes Life Technologies Buy

    Bio-IT World News Brief | Thermo Fisher Scientific announced yesterday that it has finally completed its acquisition of Life Technologies, following months of preparation and negotiations with both the FTC and European Commission to approve the purchase.

    Feb 4, 2014

  • Dicerna IPO Proves Investor Interest in RNAi

    Boston Globe | Dicerna Pharmaceuticals, a Watertown-based company developing RNA interference therapies, showed the largest first-day gains in share price for any company since 2005 when it went public on Thursday.

    Feb 3, 2014

  • January News and Product Briefs

    Bio-IT World | News and product releases from around the industry, including a collaboration for multiple sclerosis drug discovery, and new platforms for integrating NGS workflows and mimicking liver enzyme metabolism.

    Feb 3, 2014

  • Accelrys CEO on Dassault Acquisition

    Bio-IT World | Yesterday, Dassault Systèmes, a Paris-based company focused on Product Lifecycle Management (PLM), announced its intention to acquire Accelrys for approximately $750 million. Max Carnecchia, CEO of Accelrys, spoke with Bio-IT World this afternoon to give the announcement some context. 

    Jan 31, 2014

  • Johnson & Johnson Announces New Model for Data Transparency

    Xconomy | Johnson & Johnson today announced that an independent group at Yale will be empowered to review and grant scientific requests to see the full results of any clinical trial in the company's records.

    Jan 30, 2014

  • GenePeeks Readies Its In Silico Nursery

    Bio-IT World | GenePeeks, preparing to launch its service minimizing the risk of genetic disorders in children conceived through sperm donors, is awarded a patent for algorithms that create "digital children" from parental genotypes.

    Jan 30, 2014

  • Accelrys Acquired by Dassault Systemes for $750m

    Bio-IT World News Brief | Dassault Systèmes, a French company focused on Product Lifecycle Management (PLM), 3D design software and 3D digital Mock Up, announced its definitive agreement to acquire Accelrys last night in an all cash tender offer, representing a fully diluted equity value for Accelrys of approximately $750 million.

    Jan 30, 2014

  • Gene Therapy's Next Generation

    Bio-IT World | As a new generation of gene editing technologies like CRISPR and TALEN emerges, the founders of Editas Medicine think the time is right to forge ahead with gene therapy.

    Jan 29, 2014

  • Plotting the Discovery Curve: 33 New Cancer-Causing Mutations

    Bio-IT World | In a paper published in Nature last week, Broad researchers identified 33 new point mutations associated with cancer and estimated that mutations associated with at least 10% of cancer cases have been IDd. The next step is to find those mutations involved in only 5% or 2% of cancers.

    Jan 28, 2014

  • Getting to Know the New Reference Genome Assembly

    Bio-IT World | It's been almost five years since the Genome Reference Consortium released a brand-new assembly of the human reference genome. The NCBI's Valerie Schneider tells Bio-IT World what "build 38" brings to the table.

    Jan 27, 2014

  • Schizophrenia as a Spectrum

    Bio-IT World | Adding to the complex picture of schizophrenia's genetics is a recent study from Iceland, looking at those individuals who carry mutations that have been linked to schizophrenia – but who have not been diagnosed with the disorder.

    Jan 24, 2014

  • HP Launches Data Center Infrastructure Management Services

    Computerworld | HP is launching a suite of data center infrastructure management services based on the company's DCIM best practices that they call the Converged Management Framework.

    Jan 24, 2014

  • The Maddening Genetics of Schizophrenia

    Bio-IT World | The publication of the two largest genetic studies of schizophrenia ever undertaken points to several areas of the genome as key to understanding the disease. But the research also highlights just how difficult the genetics of this complicated disorder are to untangle.

    Jan 22, 2014

  • Appistry to Build Out, Support NIH Rare Disease Exome Pipeline

    Bio-IT World | The NIH’s Undiagnosed Diseases Program has turned their diploid aligner tool over to Appistry to make the pipeline “production-ready.” Appistry will host the tool in their cloud, and make the pipeline available to other users with commercial-grade support.

    Jan 22, 2014

  • JP Morgan and the Innovation Landscape

    Xconomy | Luke Timmerman sees a power shift in biotech and sums up last week's JP Morgan Healthcare Conference in one line: "It's the healthiest environment for innovation that I've seen in years."

    Jan 20, 2014

  • Acquired by IBM, Aspera Pushes On To the Science DMZ

    Bio-IT World | At Aspera, it’s business as usual, Michelle Munson told Bio-IT World this morning, after the announcement that the software company’s acquisition by IBM closed. Aspera’s software development is focused on continuing to increase raw performance; improving ease of use; integration; and developing its software developer kit and APIs.

    Jan 17, 2014

  • Catching Rare Disorders in the First Months of Life

    Bloomberg | A U.S. government-funded program is enabling hundreds of infants' genomes to be sequenced in medical centers around the country.

    Jan 16, 2014

  • FDA, 23andMe, and the Democratization of Healthcare

    Nature | Robert Green and Nita Farahany take on the FDA's treatment of 23andMe in a Nature comment today. "[R]egulatory constraints might stifle consumer genomics..." the two warned.

    Jan 15, 2014